Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.
Ritika SrivastavaAnoop KumarPublished in: International journal of clinical practice (2021)
COVID-19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.
Keyphrases
- cardiovascular events
- sars cov
- low dose
- acute respiratory distress syndrome
- coronary artery disease
- antiplatelet therapy
- coronavirus disease
- cardiovascular disease
- extracorporeal membrane oxygenation
- mechanical ventilation
- risk factors
- acute coronary syndrome
- anti inflammatory drugs
- emergency department
- percutaneous coronary intervention
- intensive care unit
- quality improvement
- adverse drug